Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
11/06/18
PDUFA date for YUPELRI™ (revefenacin) inhalation solution on November 13 TD-1473 and TD-9855 entering late-stage clinical development programs; TD-8236 advancing from research into clinic Company to host R&D Day on December 12 in New York City DUBLIN , Nov.
11/06/18
DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced the sale of its proprietary antibiotic, VIBATIV ® (telavancin), to Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused
10/30/18
DUBLIN , Oct. 30, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced that it will release financial results for the period ended September 30, 2018 and provide a business update after market close on Tuesday, November 6, 2018
10/22/18
Presented Data Demonstrated Signals of Clinical and Biomarker Activity Suggesting Localized Target Engagement following Four Weeks of Treatment in Patients with Moderately to Severely Active Ulcerative Colitis Additional Findings Highlight Minimal Systemic Exposure and No Evidence of Systemic
10/11/18
Additional Analyses of Phase 3 Program Data Highlight Efficacy Advantages for 175 mcg/day of YUPELRI in Key Patient Subgroups, Demonstrate Acceptable Cardiovascular Safety Profile DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc.
10/10/18
Presentation to Highlight Positive Data Demonstrating Localized Target Engagement and Minimal Systemic Exposure following Four Weeks of Treatment in Patients with Moderately-to-Severely Active Ulcerative Colitis DUBLIN , Oct. 10, 2018 /PRNewswire/ --  Theravance Biopharma, Inc.
10/08/18
Presentations Highlight Data of YUPELRI Compared with Tiotropium in Subpopulation of COPD Patients with Suboptimal Peak Inspiratory Flow Rates, Report Additional Data from Pivotal Phase 3 Program in Patients with Moderate to Very Severe COPD DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Oct.
10/08/18
Data from TOUR™ Observational Patient Registry Demonstrate 77.1% Clinical Response Rate for VIBATIV® (telavancin) in Patients with Monomicrobial Staphylococcus aureus Infections with Vancomycin MIC ≥ 1 µg/mL Additional TOUR Data Demonstrate Unchanged Renal Function in 68.7% of Patients Who Received
10/01/18
Data from TOUR™ Patient Registry Highlight Positive Clinical Response Rates in Patients with Monomicrobial Staphylococcus aureus Infections with Vancomycin MIC ≥ 1 µg/mL Additional TOUR Data Focus on Renal Function Impact of VIBATIV Treatment for Longer than 21 Days DUBLIN , Oct.
09/25/18
DUBLIN , Sept. 25, 2018 /PRNewswire/ --   Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018 , at 1:40 p.m. ET .  The conference will be held from October